Latest News and Press Releases

Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in...

FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026 Company to host conference call and webcast on Thursday, August 13 at 4:30 p.m. EDT AUSTIN, Texas, July 30, 2026 ...

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

Nature Communications Publishes Breakthrough Study Showing How COVID-Era Immune Memory Can Be Redirected to Fight Cancer

Paris, France, 24 juill. 2026 (GLOBE NEWSWIRE) -- Lancée pour soutenir des projets améliorant la qualité de vie des personnes atteintes de cancer, cette nouvelle édition confirme l’importance des...

American Oncology Network Expands Radiology and Imaging Program with New Physician Leaders and Advances Radiopharmaceutical Therapies

REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

A synthetic recombinant PRP is the next phase of our strategic plan in building a new therapeutic drug class aimed at treating a range of chronic diseases

Company receives positive pre-IND feedback from US FDA for CLD-401, indicating agreement on its current development strategy as it advances towards a first-in-human study; targeting dosing first...

CNSide expands coverage to ~1.2 million people in Ohio and Kentucky, bringing total contracted coverage to approximately 127 million people.